Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Free Cash Flow (2016 - 2025)

Ani Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at $41.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 162.48% year-over-year to $41.9 million; the TTM value through Dec 2025 reached $184.2 million, up 190.09%, while the annual FY2025 figure was $184.2 million, 190.09% up from the prior year.
  • Free Cash Flow for Q4 2025 was $41.9 million at Ani Pharmaceuticals, up from $31.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $78.0 million in Q2 2025 and bottomed at -$20.9 million in Q1 2022.
  • The 5-year median for Free Cash Flow is $18.1 million (2023), against an average of $16.0 million.
  • The largest annual shift saw Free Cash Flow soared 11859.06% in 2021 before it crashed 993.51% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$12.3 million in 2021, then skyrocketed by 38.76% to -$7.5 million in 2022, then skyrocketed by 663.29% to $42.5 million in 2023, then tumbled by 62.4% to $16.0 million in 2024, then skyrocketed by 162.48% to $41.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Free Cash Flow are $41.9 million (Q4 2025), $31.8 million (Q3 2025), and $78.0 million (Q2 2025).